We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Novo Nordisk has announced initial results from a Phase III clinical trial investigating NovoSeven (recombinant activated factor VII) for the treatment of people suffering from bleeding in the brain, also known as intracerebral hemorrhage.
Merck KGaA announced that the first patient has been enrolled in its global Phase III clinical study, START, assessing the efficacy and safety of Stimuvax (BLP25 liposome vaccine) as a potential treatment for patients with unresectable stage III non-small-cell lung cancer (NSCLC).
Pharmion and GPC Biotech have presented final progression-free survival (PFS) results from the double-blind, randomized, Phase III registrational trial of satraplatin, the SPARC trial.
Teva Pharmaceutical Industries announced that the FDA has granted final approval to its abbreviated new drug application (ANDA) for rabeprazole sodium delayed-release tablets, 20 mg.
BioMimetic Therapeutics has received orphan drug designation from the FDA for its recombinant human-platelet-derived growth factor (rhPDGF-BB) for the treatment of osteonecrosis of the jaw (ONJ).
Roche Laboratories, following discussion with the FDA, has terminated the Heart Spare The Nephron (STN) clinical trial due to an observed increased incidence of grade IIIA acute rejection in heart transplant patients switched from a calcineurin inhibitor (CNI) in combination with CellCept to Rapamune in combination with CellCept at 12 weeks after heart transplantation.